Media headlines about AmerisourceBergen (NYSE:ABC) have trended negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than 6,000 news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AmerisourceBergen earned a coverage optimism score of -2.30 on their scale. InfoTrie also assigned news coverage about the company an news buzz score of 10 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock’s share price in the immediate future.
Here are some of the media stories that may have effected AmerisourceBergen’s score:
- Watching the Numbers on Shares of Amerisourcebergen Corp (ABC) – Palmer News (palmerbusinessnews.com)
- Amerisourcebergen Corp (ABC) Aroon Oscillator Check-in For the Shares – Palmer News (palmerbusinessnews.com)
- Take note of This Stock:: AmerisourceBergen Corporation, (NYSE: ABC) – StockNewsWorld (stocknewsworld.com)
- opioid-settlement-opioid-distributor-shares-jump-after-18-billion-settlement-report – CBS News (cbsnews.com)
- Opioid distributors soar after reportedly offering $18 billion to settle a swath of drug crisis lawsuits (MCK, ABC, CAH) (markets.businessinsider.com)
A number of equities research analysts have issued reports on the company. Morgan Stanley lowered their price target on AmerisourceBergen from $91.00 to $83.00 and set an “equal weight” rating for the company in a research report on Friday, September 6th. Deutsche Bank initiated coverage on AmerisourceBergen in a research report on Thursday, September 12th. They issued a “hold” rating and a $91.00 target price for the company. TheStreet raised AmerisourceBergen from a “c+” rating to a “b” rating in a research report on Thursday, August 1st. Finally, ValuEngine downgraded AmerisourceBergen from a “hold” rating to a “sell” rating in a research report on Tuesday, August 6th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. AmerisourceBergen currently has an average rating of “Hold” and a consensus price target of $87.38.
Shares of NYSE ABC traded up $2.97 on Thursday, hitting $89.02. The company had a trading volume of 1,244,548 shares, compared to its average volume of 1,392,867. AmerisourceBergen has a 12-month low of $69.36 and a 12-month high of $94.85. The business has a 50 day moving average of $83.36 and a two-hundred day moving average of $82.51. The company has a quick ratio of 0.56, a current ratio of 0.95 and a debt-to-equity ratio of 1.40. The firm has a market capitalization of $17.15 billion, a P/E ratio of 13.72, a PEG ratio of 1.36 and a beta of 1.00.
AmerisourceBergen (NYSE:ABC) last issued its earnings results on Thursday, August 1st. The company reported $1.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.62 by $0.14. AmerisourceBergen had a return on equity of 47.88% and a net margin of 0.54%. The company had revenue of $45.24 billion during the quarter, compared to the consensus estimate of $45.15 billion. During the same quarter in the prior year, the business earned $1.54 earnings per share. The company’s revenue was up 4.9% compared to the same quarter last year. On average, sell-side analysts anticipate that AmerisourceBergen will post 7.05 earnings per share for the current year.
In other AmerisourceBergen news, EVP John G. Chou sold 13,997 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $81.48, for a total transaction of $1,140,475.56. Following the sale, the executive vice president now owns 65,782 shares in the company, valued at $5,359,917.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven H. Collis sold 19,905 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $89.58, for a total value of $1,783,089.90. Following the sale, the chief executive officer now owns 154,484 shares in the company, valued at approximately $13,838,676.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 109,506 shares of company stock worth $9,412,050. Insiders own 27.80% of the company’s stock.
AmerisourceBergen Company Profile
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.
Read More: What is the market perform rating?
Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.